CM – CPH continues to mock the acquisition as Halucenex expands its psychedelics lineup


We track your page views and clicks so we can continue to improve the website for our users.

Creso Pharma Limited’s (ASX: CPH, FRA: 1X8) target acquisition company Halucenex Life Sciences has nearly doubled its synthetic psilocybin supply.

Halucenex has an additional 10 grams of synthetic psilocybin from its manufacturing partner – Canada’s only manufacturer of Pharmaceutical Grade Synthetic Psilocybin – Preserved.

The additional offering makes Halucenex one of the largest GMP Grade Synthetic Psilocybin holders in Canada.

In fact, Halucenex is just one of eleven supplying companies in Canada and ensure existing relationships with manufacturing partners and significantly improve inventory levels.

The additional grammar increases Halucenex’s total inventory to 22.3 grams, providing a generous opportunity to advance and accelerate clinical trials and R&D initiatives. </ It also brings it in line with peers like MindMed (NASADAQ: MNMD, NEO: MMED) that was recently listed as the second company of its kind on NASDAQ and Compass.

MindMed is affiliated with CPH through its advisor Bruce Linton, who is also a member of MindMed’s board of directors and who founded Canopy Growth Corp. Former CEO and founder of CPH, Dr. Miri Wernli, remains a major shareholder of CPH and is Executive President and Director of MindMed.

While it is unclear how large MindMed’s psilocybin offerings are, the company’s value continues to grow based on recent research. MindMed has a market capitalization of CA $ 1.155 billion, cash on hand of CA $ 205.2 million and an enterprise value (EV) of CA $ 0.95 billion.

The $ 1.4 billion capped compass is also in the clinical trial phase developing the COMP360 psilocybin therapy for treatment-resistant depression (TRD). We are currently working on this:

Compass has a cash on hand of USD 190 million and an EV of USD 1.21 billion as of December 30, 2020.

More information on the Compass and MindMed studies can be found See our previous finfeed article: Halucenex Forms an Important Partnership As The Room Warms Up To Psychedelics

By comparison, CPH has a market cap of AU $ 200M, a cash on hand of $ 18.6M and a EV of $ 181.4 million, suggesting the company is on a huge uptrend following the completion of the Halucenex acquisition.

CPH’s position will be further strengthened when it is listed on the US OTC exchange which is now imminent. DTC eligibility to enable real-time electronic processing is expected to be granted to CPH in the near future.

Halucenex is about to begin a Phase II clinical trial to test the effectiveness of psilocybin in the treatment of PTSD .

Certainly the increased supply of psilocybin prior to the acquisition of Halucenex is an important risk reducing event.

Halucenex founder and CEO Bill Fleming made it clear how important this additional offering is and what the company’s intentions are « There is fierce competition and a bottleneck in the current psilocybin supply chain, so nearly doubling our inventory is a major derisking event, » said Fleming.

« Securing additional inventory also underscores the strength of our relationship with Canada’s only synthetic psilocybin manufacturer.

“The additional offering will unlock a number of benefits. The important thing is that it comes from the same batch as our previous inventory, which leaves a lot of leeway. A number of research and development initiatives are planned for the coming months, including new delivery integrations for a faster start and potentially improved efficacy, as well as the integration of our active ingredients in collaboration with clinical partners. We look forward to gradually updating shareholders. « 

It is important that the additional offering gives Halucenex the opportunity to increase the total number of participants in clinical studies in the upcoming phase II clinical study.

This would ensure that all participants in future Phase II and Phase III tracking and traceability studies are handled with the same consistent GMP batch.

With the additional supply of psilocybin, Halucenex can now also use GMP formulations in future dispensing methods for a faster start and incorporate other useful compounds, including those in CPH’s current range of products, to create bespoke solutions for new drug development.

« Halucenex is one of the largest, if not the largest, synthetic psilocybin owners in today GMP quality in Canada. This is an important development and will open a number of doors for the company in the medium and long term, « said Adam Blumenthal, CPH’s non-executive chairman.

 » The company now has the freedom to advance a number of R&D initiatives that have the potential to unlock new drug delivery methods and combinations, potentially leading to higher levels of care through alternative treatments. We look forward to working with Halucenex and its existing partners to advance these research initiatives. “

Short term positions in small early stage ASX companies,
with high potential and short-term price catalysts.

Focus on resource exploration, early stage technology and biotechnology.

Exceptional opportunities in a wide range of
Early stage growth sectors with strong management.

Looking for 1,000% plus returns over medium to long term stops.

Long-term positions in various industries.

I am looking for a strong management where there is traction
is established and has entered a growth phase.

S3 Consortium Pty Ltd (CAR # 433913) is an authorized corporate agent of LeMessurier Securities Pty Ltd (AFSL # 296877). The information contained in this article is for general information only. Any advice is just general advice. Neither your personal goals, your financial situation nor your needs were taken into account. Accordingly, you should consider how appropriate the advice (if any) is for these goals, financial situation, and needs before responding to the advice.

S3 Consortium Pty Ltd does and seeks business with companies listed in its articles. Investors should therefore be aware that the company may have a conflict of interest that could affect the objectivity of this article. Investors should view this article as only one factor in making an investment decision. The editors of this article also want to disclose that they can hold this stock in their portfolios and that any decision to buy this stock should be made after the buyer has made their own inquiries about the validity of information in this article.

The information contained in this article is current as of the final date. The information contained in this article is based on sources believed by S3 Consortium Pty Ltd to be reliable and publicly available. The S3 Consortium will never acquire, disclose or use “inside information”.

Founded seven years ago, is Australia’s premier and oldest website for investor and finance news, education, and expert opinion.

Finfeed was published by StocksDigital and was created daily for the comings and goings to report on ASX-listed stocks in the small-cap market.

As the first digital publication dedicated specifically to this area, Finfeed soon became the most trusted publication on the market, quickly generating over two million page views – one Number that keeps increasing. offers readers informative articles covering the latest market-moving #ASX small cap news, as well as exclusive content you won’t find anywhere else. It is aimed at those interested in investing, market education, business performance, startups and more. is the only media organization operating under the strength of a financial services license and owned by leading journalists and analysts Brands is supported.

The website aims to inform, educate and entertain content that deals with financial issues.

Finfeed is a leading source of investor and market information. Everything investors need to know about investing is written in a way that anyone can understand.

Over the years the site has expanded beyond just covering small caps to include Australia’s leading ASX-listed small, Showcase mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

The information on this website is for general information only. Any advice is just general advice. Your personal goals, your financial situation or your needs were not taken into account. Accordingly, you should consider how appropriate the advice (if any) is for these goals, financial situation, and needs before responding to the advice. S3 Consortium Pty Ltd (CAR # 433913) is an authorized corporate agent of LeMessurier Securities Pty Ltd (AFSL # 296877).

Related title :
Creso Pharma& (ASX: CPH) Halucenex secures an additional 10 grams of psilocybin Derisks acquisition as Halucenex expands its range of psychedelics



Donnez votre avis et abonnez-vous pour plus d’infos

Vidéo du jour: